These results suggest that although the pan-RTK inhibitor anlotinib has potential therapeutic efficacy in pan-KRAS-mutated NSCLC, its efficacy is not impressive, especially in the clinic. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.